Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04617054 | Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion | terminated | Phase 2 | 14 | Nuvation Bio Inc.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05868915 | HV-101 for Patients With Advanced Solid Tumors | terminated | Phase 1 | 1 | Hervor TherapeuticsINDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06334783 |
| TIL for Patients With Advanced Solid Tumor |
| terminated |
| Phase 1 |
| 5 |
| Hervor TherapeuticsINDUSTRY |
| 1 |
| Jan 21, 2026 |
| clinicaltrials |
| NCT06560632 | Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors(POLAR) | terminated | Phase 1 | 26 | Repare TherapeuticsINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT04379518 | Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients | terminated | Phase 1 / Phase 2 | 4 | Roswell Park Cancer InstituteOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | terminated | Phase 1 / Phase 2 | 73 | Ocellaris Pharma, Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04284488 | Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors | terminated | Phase 1 / Phase 2 | 40 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | terminated | Phase 1 | 78 | Fusion Pharmaceuticals Inc.INDUSTRY | 3 | Jan 7, 2026 | clinicaltrials |
| NCT06337630 | A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors(POP-ART) | terminated | Phase 1 | 10 | Institut CurieOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT06198426 | A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 5 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 2 | Dec 30, 2025 | clinicaltrials |
| NCT03993379 | PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors | terminated | Phase 2 | 3 | CytomX TherapeuticsINDUSTRY | 5 | Dec 26, 2025 | clinicaltrials |
| NCT06488716 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 12 | Genentech, Inc.INDUSTRY | 4 | Dec 24, 2025 | clinicaltrials |
| NCT06509906 | M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) | terminated | Phase 1 | 3 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 5 | Dec 18, 2025 | clinicaltrials |
| NCT03968653 | Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors | terminated | Phase 1 | 76 | Debiopharm International SAINDUSTRY | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05147272 | Study of RP-6306 With Gemcitabine in Advanced Solid Tumors | terminated | Phase 1 | 67 | Debiopharm International SAINDUSTRY | 3 | Dec 5, 2025 | clinicaltrials |
| NCT05147350 | Study of RP-6306 With FOLFIRI in Advanced Solid Tumors(MINOTAUR) | terminated | Phase 1 | 38 | Debiopharm International SAINDUSTRY | 4 | Dec 5, 2025 | clinicaltrials |
| NCT04276376 | Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors(ARIANES) | terminated | Phase 2 | 130 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05252416 | (VELA) Study of BLU-222 in Advanced Solid Tumors | terminated | Phase 1 | 50 | Blueprint Medicines CorporationINDUSTRY | 3 | Nov 28, 2025 | clinicaltrials |
| NCT06232408 | LIONS (PLK4 Inhibitor in Advanced Solid Tumors) | terminated | Phase 1 | 29 | Repare TherapeuticsINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT06289894 | A Study of BRY805 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 13 | BioRay Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT02936102 | A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. | terminated | Phase 1 | 154 | Novartis PharmaceuticalsINDUSTRY | 9 | Nov 14, 2025 | clinicaltrials |
| NCT05252390 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 82 | Nuvation Bio Inc.INDUSTRY | 2 | Nov 6, 2025 | clinicaltrials |
| NCT05798611 | Study of ART0380 in Patients With Biologically Selected Solid Tumors(ARTIST) | terminated | Phase 2 | 36 | Artios Pharma LtdINDUSTRY | 3 | Nov 6, 2025 | clinicaltrials |
| NCT03770494 | A Study of LY3405105 in Participants With Advanced Cancer | terminated | Phase 1 | 54 | Eli Lilly and CompanyINDUSTRY | 5 | Nov 4, 2025 | clinicaltrials |
| NCT04972110 | Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors(ATTACC) | terminated | Phase 1 / Phase 2 | 156 | Repare TherapeuticsINDUSTRY | 1 | Oct 30, 2025 | clinicaltrials |
| NCT05169437 | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors(PAVO) | terminated | Phase 2 | 22 | Tempus AIINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT02597036 | A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors | terminated | Phase 1 | 62 | Eli Lilly and CompanyINDUSTRY | 4 | Oct 23, 2025 | clinicaltrials |
| NCT02711137 | Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 137 | Incyte CorporationINDUSTRY | 3 | Oct 21, 2025 | clinicaltrials |
| NCT02959437 | Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) | terminated | Phase 1 / Phase 2 | 70 | Incyte CorporationINDUSTRY | 3 | Oct 21, 2025 | clinicaltrials |
| NCT03144661 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | terminated | Phase 1 | 25 | Incyte CorporationINDUSTRY | 2 | Oct 21, 2025 | clinicaltrials |
| NCT05646797 | A Study of ASP2074 in Adults With Solid Tumors | terminated | Phase 1 | 23 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Oct 20, 2025 | clinicaltrials |
| NCT05859464 | A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 34 | Zai Lab (Hong Kong), Ltd.INDUSTRY | 3 | Oct 20, 2025 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT06336148 | A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 10 | Actym Therapeutics, Inc.INDUSTRY | 2 | Oct 15, 2025 | clinicaltrials |
| NCT04982926 | A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer | terminated | Phase 1 | 29 | Taiho Oncology, Inc.INDUSTRY | 2 | Oct 14, 2025 | clinicaltrials |
| NCT03522142 | A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies | terminated | Phase 1 | 83 | Incyte CorporationINDUSTRY | 5 | Oct 9, 2025 | clinicaltrials |
| NCT05976334 | An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 3 | TakedaINDUSTRY | 1 | Oct 6, 2025 | clinicaltrials |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | terminated | Phase 2 | 23 | Day One Biopharmaceuticals, Inc.INDUSTRY | 7 | Oct 2, 2025 | clinicaltrials |
| NCT05221320 | Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies | terminated | Phase 2 | 47 | BioMed Valley Discoveries, IncINDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05821777 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 25 | Centessa Pharmaceuticals (UK) LimitedINDUSTRY | 2 | Sep 25, 2025 | clinicaltrials |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 23 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04674748 | To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550 | terminated | Phase 1 | 3 | Incyte Biosciences Japan GKINDUSTRY | 1 | Sep 24, 2025 | clinicaltrials |
| NCT06270082 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | terminated | Phase 1 | 75 | Ikena OncologyINDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06182579 | Phase I Study of RiMO-401 With Radiation in Advanced Tumors | terminated | Phase 1 | 5 | Coordination Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT04242147 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors | terminated | Phase 1 | 45 | Kadmon, a Sanofi CompanyINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05904496 | A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 44 | BeiGeneINDUSTRY | 4 | Sep 16, 2025 | clinicaltrials |
| NCT06175221 | Autologous TLPO Vaccine Basket | terminated | Phase 2 | 63 | Elios Therapeutics, LLCINDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT05707676 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001）(MEETCD8-001) | terminated | Phase 1 | 40 | L & L Bio Co., Ltd., Ningbo, ChinaINDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT06226766 | JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors | terminated | Phase 1 / Phase 2 | 11 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 21, 2026source: clinicaltrials